Skip to main content
SpringerLink
Log in

Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions

  • Educational Review
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Natural history studies have shown that peritoneal carcinomatosis is uniformly fatal, with a median survival in the range of approximately 6 months. For more than a decade, a handful of centers have pursued aggressive intraperitoneal cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy as an alternative approach to this disease. Strict selection criteria, variation in intraperitoneal chemotherapy, and the vagaries of what represents “cytoreductive surgery” make many of our colleagues, particularly those in medical oncology, reticent to refer patients for such an aggressive therapy. This article establishes a conceptual framework for understanding the role of intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal surface malignancy. This procedure continues to make advancements in the oncological community despite formidable challenges. The advancement of centers of excellence and the initiation of further phase II trials will help to define the optimal treatment approach for peritoneal carcinomatosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 2001;8:632–7

    PubMed  Google Scholar 

  2. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545–50

    Article  PubMed  Google Scholar 

  3. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999–1003.

    PubMed  Google Scholar 

  4. Koga S. [Prophylactic and therapeutic continuous hyperthermic peritoneal perfusion for peritoneal metastases of gastric cancer]. Gan No Rinsho 1985;31:1103–5

    PubMed  Google Scholar 

  5. Fizazi K, Doubre H, Le Chevalier T et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003;21:349–54

    Article  PubMed  Google Scholar 

  6. Spratt JS, Adcock RA, Sherrill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res 1980;40:253–5

    PubMed  Google Scholar 

  7. Fujimoto S, Shrestha RD, Kokubun M et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36–41

    PubMed  Google Scholar 

  8. Meyers MA. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med 1973;119:198–206

    PubMed  Google Scholar 

  9. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465–72

    Article  PubMed  Google Scholar 

  10. Averbach AM, Jacquet P, Sugarbaker PH. Surgical technique and colorectal cancer: impaction on local recurrence and survival. Tumori 1995;81:65–71

    PubMed  Google Scholar 

  11. Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 1987;102:71–8

    PubMed  Google Scholar 

  12. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480–7

    Google Scholar 

  13. Dedrick RL. Interspecies scaling of regional drug delivery. J Pharm Sci 1986;75:1047–52

    Google Scholar 

  14. Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol 1985;248:F413–F424

    PubMed  Google Scholar 

  15. Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 1994;46:685–9

    PubMed  Google Scholar 

  16. Speyer JL, Collins JM, Dedrick RL, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980;40:567–72

    PubMed  Google Scholar 

  17. Israel VK, Jiang C, Muggia FM, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 1995;37:32–8

    PubMed  Google Scholar 

  18. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982;42:4265–9

    PubMed  Google Scholar 

  19. Bartlett DL, Buell JF, Libutti SK et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83:1251–61

    Article  PubMed  Google Scholar 

  20. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118:547–50

    Article  PubMed  Google Scholar 

  21. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998;16:2620–4

    PubMed  Google Scholar 

  22. Dikomey E, Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol 1992;61:221–33

    PubMed  Google Scholar 

  23. Roti Roti JL, Kampinga HH, Malyapa RS, Wright WD, vanderwaal RP, Xu M, et al. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones 1998;3:245–55

    Article  PubMed  Google Scholar 

  24. Glehen O, Osinsky D, Cotte E et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10:863–9

    Google Scholar 

  25. Elias D, Bonnay M, Puizillou JM et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267–72

    Article  PubMed  Google Scholar 

  26. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 1980;40:1165–8

    PubMed  Google Scholar 

  27. El Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004;6:117–27

    PubMed  Google Scholar 

  28. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg 2001;18:260–73

    Article  PubMed  Google Scholar 

  29. Raftery AT. Regeneration of peritoneum: a fibrinolytic study. J Anat 1979;129:659–64

    PubMed  Google Scholar 

  30. Markman M, Cleary S, Howell SB, Lucas WE. Complications of extensive adhesion formation after intraperitoneal chemotherapy. Surg Gynecol Obstet 1986;162:445–8

    Google Scholar 

  31. Topuz E, Saip P, Aydiner A, Salihoglu Y, Aydin Y, Topuzlu C et al. Catheter complications associated with intraperitoneal chemotherapy. Eur J Gynaecol Oncol 1998;19:275–9

    PubMed  Google Scholar 

  32. Kodera Y, et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999;72:60–4

    Article  PubMed  Google Scholar 

  33. Basha G, Ghirardi M, Geboes K, Yap SH, Penninckx F. Limitations of peritoneal lavage with antiseptics in prevention of recurrent colorectal cancer caused by tumor-cell seeding: experimental study in rats. Dis Colon Rectum 2000;43:1713–8

    PubMed  Google Scholar 

  34. Sweitzer KL, Nathanson SD, Nelson LT, Zachary C. Irrigation does not dislodge or destroy tumor cells adherent to the tumor bed. J Surg Oncol 1993;53:184–90

    PubMed  Google Scholar 

  35. Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol 1983;22:95–9

    PubMed  Google Scholar 

  36. Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys 1983;9:361–5

    PubMed  Google Scholar 

  37. Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin North Am 2003;12:561–83

    Google Scholar 

  38. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000;58:96–107

    Article  PubMed  Google Scholar 

  39. Moertel CG. Peritoneal mesothelioma. Gastroenterology 1972;63:346–50

    PubMed  Google Scholar 

  40. Chan PS, Balfour TW, Bourke JB, Smith PG. Peritoneal nesothelioma. Br J Surg 1975;62:576–80

    PubMed  Google Scholar 

  41. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD et al. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65–73

    Article  PubMed  Google Scholar 

  42. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 1981;75:311–3

    PubMed  Google Scholar 

  43. Sadeghi B, Arvieux C, Glehen O et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358–63

    Article  PubMed  Google Scholar 

  44. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6

    Article  PubMed  Google Scholar 

  45. Antman KH, Osteen RT, Klegar KL, Amato DA, Pomfret EA, Lanson DA, Corson JM et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet 1985;2:977–81

    Article  PubMed  Google Scholar 

  46. Shen P, Levine EA, Hall J et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003;138:26–33

    PubMed  Google Scholar 

  47. Loggie BW, Perini M, Fleming RA, Russell GB, Geisinger K. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 1997;63:137–43

    Google Scholar 

  48. de Bree E, et al. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 2004;86:64–73

    Article  PubMed  Google Scholar 

  49. Kubik-Huch RA, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761–7

    Google Scholar 

  50. Low RN, et al. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997;204:513–20

    Google Scholar 

  51. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17–21

    Article  PubMed  Google Scholar 

  52. Iwamoto A, et al. [Intraoperative chemotherapy with intraperitoneal activated carbon particles adsorbing mitomycin C against peritoneal dissemination of gastric cancer]. Gan To Kagaku Ryoho 1989;16:2748–51

    PubMed  Google Scholar 

  53. Fujimoto S, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997;79:884–91

    Article  PubMed  Google Scholar 

  54. Ouchi K, et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 1998;69:41–4

    Article  PubMed  Google Scholar 

  55. Hagiwara A, et al. Extensive gastrectomy and carbon-adsorbed mitomycin C for gastric cancer with peritoneal metastases. Case reports of survivors and their implications. Hepatogastroenterology 1999;46:1673–7

    Google Scholar 

  56. Ronnett BM, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 1995;19:1390–408

    PubMed  Google Scholar 

  57. Gilly FN, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124–9

    Google Scholar 

  58. Beaujard AC, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000;88:2512–9

    Article  PubMed  Google Scholar 

  59. Rey Y, Porcheron J, Talabard JN, Szafnicki K, Balique JG. [Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia]. Ann Chir 2000;125:631–42

    Article  PubMed  Google Scholar 

  60. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–31

    Article  PubMed  Google Scholar 

  61. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004;14:35–41

    Article  PubMed  Google Scholar 

  62. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587–93

    Article  PubMed  Google Scholar 

  63. Tentes AA, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003;29:69–73

    Article  PubMed  Google Scholar 

  64. Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999;35:413–9

    Article  PubMed  Google Scholar 

  65. Sebbag G, Sugarbaker PH. Peritoneal mesothelioma proposal for a staging system. Eur J Surg Oncol 2001;27:223–4

    Article  PubMed  Google Scholar 

  66. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43(Suppl):S15–25

    Article  PubMed  Google Scholar 

  67. Leunig M, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 1992;52:487–90

    PubMed  Google Scholar 

  68. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022–32

    PubMed  Google Scholar 

  69. Culliford AT, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001;8:787–95

    PubMed  Google Scholar 

  70. Marcus EA, et al. Prognostic factors affecting survival in patients with colorectal carcinomatosis. Cancer Invest 1999;17:249–52

    PubMed  Google Scholar 

  71. Glehen O, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003;21:799–806

    Article  PubMed  Google Scholar 

  72. Yonemura Y, et al. A new surgical approach (peritonectomy) for the treatment of peritoneal dissemination. Hepatogastroenterology 1999;46:601–9

    PubMed  Google Scholar 

  73. Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999;23:23–9

    Article  PubMed  Google Scholar 

  74. Sugarbaker PH, et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996;30:233–80

    PubMed  Google Scholar 

  75. Stephens AD, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790–6

    Article  PubMed  Google Scholar 

  76. Ahmad SA, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004;11:387–92

    Article  PubMed  Google Scholar 

  77. McQuellon RP, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155–62

    Google Scholar 

  78. Alexander HR, Mavroukakis SM, Libutti SK, et al. Impact of tumor resection and intraperitoneal chemotherapy on health related quality of life in patients with peritoneal surface malignancies. In: Proceedings of the 57th Annual Society of Surgical Oncology Cancer Symposium. March 18, 2004. Philadelphia: Lippincott, Williams, and Wilkens, 2004

  79. Glehen O, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20–6

    Article  PubMed  Google Scholar 

  80. Witkamp AJ, et al. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001;88:458–63

    Article  PubMed  Google Scholar 

  81. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum 2000;43:1341–6

    Google Scholar 

  82. Glehen O, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747–54

    Article  PubMed  Google Scholar 

  83. Verwaal VJ, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43

    Article  PubMed  Google Scholar 

  84. Glehen O, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–92

    Article  PubMed  Google Scholar 

  85. Hall JJ, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454–63

    Article  PubMed  Google Scholar 

  86. Yonemura Y, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 2001;48:1776–82

    PubMed  Google Scholar 

  87. Yonemura Y, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437–44

    PubMed  Google Scholar 

  88. Deraco M, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001;87:120–6

    PubMed  Google Scholar 

  89. Elias D, et al. [Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy]. Gastroenterol Clin Biol 2003;27:407–12

    PubMed  Google Scholar 

  90. Deraco M, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393–8

    Article  PubMed  Google Scholar 

  91. Stewart JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2004;12(Suppl):S32 (abstr 79)

    Google Scholar 

  92. Costamagna D, Scuderi S, Vaira M, Barone R, De Simone M. [Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy]. Tumori 2003;89:40–2

    PubMed  Google Scholar 

  93. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003;12:605–21, xi

    Google Scholar 

  94. Park BJ, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999;6:582–90

    Article  PubMed  Google Scholar 

  95. Deraco M, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003;83:147–53

    Article  PubMed  Google Scholar 

  96. Feldman AL, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–7

    Article  PubMed  Google Scholar 

  97. Kinsella TJ, Sindelar WF, Lack E, Glatstein E, Rosenberg SA. Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. J Clin Oncol 1988;6:18–25

    PubMed  Google Scholar 

  98. Karakousis CP, Gerstenbluth R, Kontzoglou K, Driscoll DL. Retroperitoneal sarcomas and their management. Arch Surg 1995;130:1104–9

    PubMed  Google Scholar 

  99. Pirayesh A, et al. The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature. Eur J Surg Oncol 2001;27:491–7

    Article  PubMed  Google Scholar 

  100. Rossi CR, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer 2004;100:1943–50

    Article  PubMed  Google Scholar 

  101. Levine EA. Problems of success and problems of failure: recurrent disease after cytoreductive surgery and intraperitoneal chemoperfusion. Ann Surg Oncol 2004;11:351–3

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology Service, Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina , 27157

    John H. Stewart IV MD, Perry Shen MD & Edward A. Levine MD

Authors
  1. John H. Stewart IV MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Perry Shen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward A. Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward A. Levine MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, J.H., Shen, P. & Levine, E.A. Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions. Ann Surg Oncol 12, 765–777 (2005). https://doi.org/10.1245/ASO.2005.12.001

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2005.12.001

Keywords

Search

Navigation